RxDoctor Payments Data

Elizabeth Rivlin

Family · Bowling Green, VANPI 1316665250

Payments from drug & device makers

$692in general payments, 2019–2025

Across 33 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$229
  • Organon$114
  • Amgen$50
  • Pfizer$50
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • AstraZeneca$44
  • plus $158 from 6 others

What the payments were for

  • Food & beverage$67397%
  • Education$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$692 in reported general payments places this provider in the 65th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$3,110
Medicare patients
34
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol91$95,971
TrulicityDulaglutide67$80,666
OzempicSemaglutide67$70,744
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$38,506
JardianceEmpagliflozin24$36,927
EliquisApixaban33$33,060
Breo ElliptaFluticasone/Vilanterol35$21,833
JanuviaSitagliptin Phosphate16$17,683
XareltoRivaroxaban12$17,653
MyrbetriqMirabegron16$16,483
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$7,865
InvokanaCanagliflozin13$7,318
Duloxetine Hcl41$3,868
AbrysvoRsv Vacc, Pref A And Pref B/Pf11$3,338
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$44$95,97191 claims
Lilly USA, LLCTrulicity$33$80,66667 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix$18$70,77191 claims
Novo NordiskOzempic$229$70,74467 claims
Boehringer IngelheimJardiance$19$36,92724 claims
PfizerEliquis, Abrysvo$50$36,39844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,332 family providers in Virginia.

Other family in Bowling Green

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →